関連する実験動画
Updated: Sep 10, 2025

09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
9.5K
エタクリン酸は,血液・迷宮障壁経由でゲンタミシンオトキシ性を調節する
Liling Li1, Jingqian Tan1, Dan Chen1
1Department of Otolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guang Zhou, Guangdong, China, 510630.
Hearing research
|August 27, 2025
まとめ
エタクリン酸 (EA) はゲンタミシン (GM) の耳毒性を悪化させ,重度の聴覚障害を引き起こす. N-アセチルシステイン (NAC) は,特に早期に投与された場合,この損傷から保護し,薬物による聴覚障害を予防する戦略を提供します.
科学分野:
- 耳毒性研究
- 薬理学について
- 神経科学
背景:
- アミノグリコシド抗生物質であるジェンタミシン (GM) は耳毒性を引き起こし,臨床使用を制限する.
- 他の薬との併用は,GM誘発の耳毒性を悪化させる可能性があります.
- これらの相互作用を理解することは,患者の安全にとって極めて重要です.
研究 の 目的:
- ジェンタミシンとエタクリン酸 (EA) の結合による耳毒性メカニズムを調査する.
- GMとEAの結合毒性に対するN-アセチルシステイン (NAC) の保護効果を評価する.
- 遺伝子組み換えのオート毒性における血液・迷宮障壁 (BLB) の役割を調査する.
主な方法:
- C57BL/6 Jマウスを用いた系統的調査.
- GMとEAの投与量は量に依存する.
- 聴覚神経の退化,そしてスパイラル・ギャングリオン・ニューロンの損傷の評価
- 全身性肝臓毒性マーカーの評価
- BLBの整体性とペリサイトによる修復の分析
- N-アセチルシステイン (NAC) の介入は,異なる時間点で行われました.
主要な成果:
- 静脈内投与はより重症である.
- EAは,GMOのオート毒性を相乗的に強化し,毛細胞の減少と神経変性を引き起こしました.
- EAはBLBの整合性を破壊し,補償的な修復メカニズムを起動しました.
- NACの介入により,GMとEAの結合毒性が著しく減少し,前処理が最良の結果を示した.
- 遅延されたEA投与は毛細胞の損傷を軽減し,NACは神経およびシナプス損傷を改善しました.
結論:
- エタクリン酸は,血バリアのホメオスタシスを破壊することによって,ゲンタミシンのオート毒性を悪化させる.
- N- アセチルシステインは,ゲンタミシンとエタクリン酸の結合による耳毒性に対する有意な保護を提供します.
- N- アセチルシステインの投与タイミングは,薬剤による聴覚障害を予防する潜在的戦略を提供するため,その保護効果には極めて重要です.
さらに関連する動画
関連する概念動画
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
Drug Elimination by Renal Route: Tubular Secretion
2.5K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.5K
Renal Drug Excretion: Tubular Secretion
339
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
339
Drug Elimination by Renal Route: Tubular Reabsorption
3.9K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.9K
Glomerular Filtration Rate and its Regulation
3.3K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.3K
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274

